典型文献
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study
文献摘要：
Background::Chemotherapy is a common treatment for advanced hepatocellular carcinoma, but the effect is not satisfactory. The study aimed to retrospectively evaluate the effects of adding all-trans-retinoic acid (ATRA) to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) for advanced hepatocellular carcinoma (HCC).Methods::We extracted the data of patients with advanced HCC who underwent systemic chemotherapy using FOLFOX4 or ATRA plus FOLFOX4 at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University, and Zhejiang Sian International Hospital and retrospectively compared for overall survival. The Cox proportional hazards model was used to calculate the hazard ratios for overall survival and disease progression after controlling for age, sex, and disease stage.Results::From July 2013 to July 2018, 111 patients with HCC were included in this study. The median survival duration was 14.8 months in the ATRA plus FOLFOX4 group and 8.2 months in the FOLFOX4 only group (
P < 0.001). The ATRA plus FOLFOX4 group had a significantly longer median time to progression compared with the FOLFOX4 group (3.6 months
vs. 1.8 months,
P < 0.001). Hazard ratios for overall survival and disease progression were 0.465 (95% confidence interval: 0.298–0.726;
P = 0.001) and 0.474 (0.314–0.717;
P < 0.001) after adjusting for potential confounders, respectively.
Conclusion::ATRA plus FOLFOX4 significantly improves the overall survival and time to disease progression in patients with advanced HCC.
文献关键词：
Hepatocellular carcinoma;ATRA plus FOLFOX4;Overall survival;All-trans-retinoic acid;Fluorouracil;Leucovorin;Oxaliplatin
中图分类号：
作者姓名：
Sun Juxian;Liu Chang;Shi Jie;Wang Nanya;Jiang Dafeng;Mao Feifei;Gu Jingwen;Zhou Liping;Shen Li;Yee Lau Wan;Cheng Shuqun
作者机构：
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Integrative Oncology, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Outpatient Department, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 200433, China;Department of Oncology, First Hospital of Jilin University, Changchun, Jilin 130000, China;Department of Oncology Zhejiang Sian International Hospital, Jiaxing, Zhejiang 314000, China;Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200040, China;Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR 999077, China
文献出处：
引用格式：
[1]Sun Juxian;Liu Chang;Shi Jie;Wang Nanya;Jiang Dafeng;Mao Feifei;Gu Jingwen;Zhou Liping;Shen Li;Yee Lau Wan;Cheng Shuqun-.A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study)[J].中华医学杂志（英文版）,2022(19):2338-2343
A类：
infusional,leucovorin,Sian,Leucovorin
B类：
novel,chemotherapy,strategy,advanced,hepatocellular,carcinoma,multicenter,study,Background,Chemotherapy,common,treatment,but,not,satisfactory,aimed,retrospectively,evaluate,effects,adding,trans,retinoic,acid,ATRA,fluorouracil,oxaliplatin,FOLFOX4,HCC,Methods,We,extracted,data,patients,who,underwent,systemic,using,plus,Eastern,Hepatobiliary,Surgery,Hospital,First,Jilin,University,Zhejiang,International,compared,overall,survival,Cox,proportional,hazards,model,was,used,calculate,ratios,disease,progression,after,controlling,sex,stage,Results,From,July,were,included,this,median,duration,months,group,only,had,significantly,longer,Hazard,confidence,interval,adjusting,potential,confounders,respectively,Conclusion,improves,Hepatocellular,Overall,All,Fluorouracil,Oxaliplatin
AB值：
0.468247
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
